Circulating tumor DNA came to be considered a suitable cancer biomarker due to the identification of KRAS mutations in ctDNA from the blood of PDAC patients.13 The comprehensive genomic analysis for the cancers was expected to prove useful as a novel molecular diagnostic method. Here, KRAS is linked to cancer.